Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
1.640 GBX | +0,28 % | +3,60 % | +13,12 % |
25/04 | Actualización del sector: Las acciones de atención médica caen en las operaciones de la tarde | MT |
25/04 | GSK demanda a Pfizer y BioNTech por las patentes de ARNm en las vacunas Covid-19 | MT |
Resumen de negocios
Número de empleados: 70 212
Ventas por actividad
GBP en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Commercial Operations
100,0
%
| 29 324 | 100,0 % | 30 328 | 100,0 % | +3,42 % |
Ventas por región
GBP en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
52,2
%
| 14 542 | 49,6 % | 15 820 | 52,2 % | +8,79 % |
Rest of World
45,6
%
| 14 087 | 48,0 % | 13 815 | 45,6 % | -1,93 % |
United Kingdom
2,3
%
| 695 | 2,4 % | 693 | 2,3 % | -0,29 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 01/05/10 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 01/05/23 |
James Ford
CMP | Compliance Officer | - | 01/08/95 |
Amy Altshul
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Tech/Sci/R&D Officer | - | 01/01/18 | |
Tony Wood
CTO | Chief Tech/Sci/R&D Officer | - | 01/08/17 |
Hal Barron
BRD | Director/Board Member | 62 | 01/01/18 |
David Redfern
PRN | Corporate Officer/Principal | 57 | 01/01/94 |
Frannie DeFranco
PRN | Corporate Officer/Principal | - | 01/09/10 |
Claire Lund
PRN | Corporate Officer/Principal | - | - |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 01/05/23 |
Jonathan Symonds
CHM | Chairman | 66 | 01/09/19 |
Urs Rohner
BRD | Director/Board Member | 65 | 01/01/15 |
Hal Barron
BRD | Director/Board Member | 62 | 01/01/18 |
Vishal Sikka
BRD | Director/Board Member | 57 | 18/07/22 |
Wendy Becker
BRD | Director/Board Member | 58 | 01/10/23 |
Charles Bancroft
BRD | Director/Board Member | 65 | 01/05/20 |
Emma Walmsley
CEO | Chief Executive Officer | 55 | 01/05/10 |
Director/Board Member | 66 | 01/09/22 | |
Jesse Goodman
BRD | Director/Board Member | 72 | 01/01/16 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 4 400 765 312 | 4 071 678 492 ( 92,52 %) | 255 885 366 ( 5,815 %) | 92,52 % |
Participaciones
Nombre | Acciones | % | Valoración |
---|---|---|---|
127 054 524 | 75.00% | 2 960 098 513 $ | |
HALEON PLC 4.22% | 385 320 110 | 4.22% | 1 621 384 638 $ |
VIR BIOTECHNOLOGY, INC. 6.33% | 8 550 954 | 6.33% | 86 621 164 $ |
WAVE LIFE SCIENCES LTD. 11.44% | 13 983 761 | 11.44% | 86 279 805 $ |
263 029 794 | 82.59% | 80 253 020 $ | |
HALEON PAKISTAN LIMITED 85.79% | 100 423 259 | 85.79% | 70 443 903 $ |
LYELL IMMUNOPHARMA, INC. 11.91% | 30 253 189 | 11.91% | 67 464 611 $ |
CUREVAC N.V. 7.41% | 16 591 937 | 7.41% | 50 273 569 $ |
GLAXOSMITHKLINE S.A.E 91.20% | 76 161 378 | 91.20% | 48 251 279 $ |
DONG-A ST CO., LTD. 8.38% | 722 016 | 8.38% | 39 741 046 $ |
Información de la empresa
Empresas del grupo
Nombre | Categoría y sector |
---|---|
GlaxoSmithKline Capital Plc
|
Finance/Rental/Leasing
|
GlaxoSmithKline Biologicals NV
GlaxoSmithKline Biologicals NV BiotechnologyHealth Technology GlaxoSmithKline Biologicals SA manufactures vaccines for diseases such as hepatitis, influenza, rubella, and typhoid fever. Its activities include overall strategy, research and development, clinical trials, regulatory matters, production, quality control, marketing, and distribution. The company has partnership with WHO and UNICEF. GlaxoSmithKline Biologicals was founded in 1945 and is headquartered in Rixensart, Belgium. |
Biotechnology
|
Eskaylab Ltd.
Eskaylab Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 1908, Eskaylab Ltd. is a testing British laboratory company that operates in Middlesex, UK. |
Miscellaneous Commercial Services
|
Horlicks Ltd.
Horlicks Ltd. Beverages: AlcoholicConsumer Non-Durables Horlicks Ltd. manufactures and distributes infant food products. The products it offers are Horlicks traditional, light and light chocolate. The company was founded on December 11, 1925 and is headquartered in Brentford, the United Kingdom. |
Beverages: Alcoholic
|
Novartis Consumer Health SA
Novartis Consumer Health SA Pharmaceuticals: MajorHealth Technology Part of GSK Plc, Novartis Consumer Health SA is a private company based in Basel, Switzerland. |
Pharmaceuticals: Major
|
Glaxo Group Ltd.
Glaxo Group Ltd. Pharmaceuticals: MajorHealth Technology Founded in 1935, Glaxo Group Ltd. is a subsidiary of GSK Plc. The private company is based in Middlesex, UK. At GSK, we unite science, technology and talent to get ahead of disease together. |
Pharmaceuticals: Major
|
GlaxoSmithKline Finance Plc
|
Finance/Rental/Leasing
|
Setfirst Ltd.
Setfirst Ltd. Financial ConglomeratesFinance Part of GSK Plc, Setfirst Ltd. functions as an investment holding British company. The private company is based in Middlesex, UK. |
Financial Conglomerates
|
GlaxoSmithKline GmbH & Co. KG
GlaxoSmithKline GmbH & Co. KG Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline GmbH & Co. KG is a German pharmaceutical company. The private company is based in Munich, Germany. The CEOs of the company are Jean-Bernard Siméon, Adrian Bauer. |
Pharmaceuticals: Major
|
Ventas por actividad
Ventas por región
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
+13,12 % | 83,75 mil M | |
+24,17 % | 556 mil M | |
-6,33 % | 354 mil M | |
+19,90 % | 331 mil M | |
+7,95 % | 296 mil M | |
+13,45 % | 233 mil M | |
+6,04 % | 201 mil M | |
-10,51 % | 193 mil M | |
-12,26 % | 143 mil M | |
-6,47 % | 144 mil M |
- Bolsa de valores
- Acciones
- Acción GSK
- Empresa GSK plc